[go: up one dir, main page]

FR13C0021I2 - EXENDIN-4 CONJUGATES AND THEIR MEDICAL USE - Google Patents

EXENDIN-4 CONJUGATES AND THEIR MEDICAL USE

Info

Publication number
FR13C0021I2
FR13C0021I2 FR13C0021C FR13C0021C FR13C0021I2 FR 13C0021 I2 FR13C0021 I2 FR 13C0021I2 FR 13C0021 C FR13C0021 C FR 13C0021C FR 13C0021 C FR13C0021 C FR 13C0021C FR 13C0021 I2 FR13C0021 I2 FR 13C0021I2
Authority
FR
France
Prior art keywords
conjugates
exendin
medical use
useful
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0021C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of FR13C0021I1 publication Critical patent/FR13C0021I1/fr
Application granted granted Critical
Publication of FR13C0021I2 publication Critical patent/FR13C0021I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.
FR13C0021C 1999-07-12 2013-04-02 EXENDIN-4 CONJUGATES AND THEIR MEDICAL USE Active FR13C0021I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14359199P 1999-07-12 1999-07-12
EP99610043A EP1076066A1 (en) 1999-07-12 1999-08-09 Peptides for lowering blood glucose levels
PCT/DK2000/000393 WO2001004156A1 (en) 1999-07-12 2000-07-12 Peptides that lower blood glucose levels
EP00945656A EP1196444B8 (en) 1999-07-12 2000-07-12 Exendin-4 conjugates and their medical use

Publications (2)

Publication Number Publication Date
FR13C0021I1 FR13C0021I1 (en) 2013-05-03
FR13C0021I2 true FR13C0021I2 (en) 2013-08-16

Family

ID=26153727

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0021C Active FR13C0021I2 (en) 1999-07-12 2013-04-02 EXENDIN-4 CONJUGATES AND THEIR MEDICAL USE

Country Status (19)

Country Link
US (1) US20070111940A1 (en)
EP (4) EP1076066A1 (en)
JP (4) JP4332314B2 (en)
CN (1) CN1229390C (en)
AT (2) ATE551362T1 (en)
AU (2) AU781338B2 (en)
BE (1) BE2013C033I2 (en)
CA (2) CA2680437A1 (en)
CY (2) CY1113347T1 (en)
DE (1) DE60003182T2 (en)
DK (3) DK1196444T3 (en)
ES (3) ES2529578T3 (en)
FR (1) FR13C0021I2 (en)
IL (4) IL147293A0 (en)
LU (1) LU92175I2 (en)
NZ (1) NZ517012A (en)
PT (3) PT1196444E (en)
SI (2) SI1329458T1 (en)
WO (1) WO2001004156A1 (en)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801571D0 (en) 1998-05-05 1998-05-05 Wapharm Ab Melanocortin-1 receptor selective compounds
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
DK1326630T3 (en) 2000-09-18 2008-09-15 Sanos Bioscience As Use of GLP-2 peptides
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
CN1158304C (en) * 2001-05-10 2004-07-21 上海华谊生物技术有限公司 Antibacterial frog skin peptide derivative
CN1162446C (en) * 2001-05-10 2004-08-18 上海华谊生物技术有限公司 Insulinotropic hormone secretion peptide derivative
JP5562510B2 (en) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス Stable formulation of modified GLP-1
JP2005501058A (en) 2001-07-31 2005-01-13 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ GLP-1, EXENDIN-4, peptide analogue thereof and use thereof
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
PL205971B1 (en) 2001-09-24 2010-06-30 Imp Innovations Ltd Modification of feeding behavior
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
AU2003226913A1 (en) * 2002-04-04 2003-10-20 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
MXPA04012497A (en) * 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 and methods for treating diabetes.
AU2003273300A1 (en) * 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2004035623A2 (en) * 2002-10-02 2004-04-29 Zealand Pharma A/S Stabilized exendin-4 compounds
WO2004037859A1 (en) * 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1 derivatives and transmicosal absorption preparations thereof
US6818721B2 (en) 2002-12-02 2004-11-16 Rpo Pty Ltd. Process for producing polysiloxanes and use of the same
EP1688148A1 (en) * 2002-12-03 2006-08-09 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
EP1569682A2 (en) * 2002-12-03 2005-09-07 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
WO2004078777A2 (en) * 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
DE10314610A1 (en) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (en) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituted benzoylureido-o-benzoylamides, process for their preparation and their use
RU2401276C2 (en) * 2003-09-19 2010-10-10 Ново Нордиск А/С Glucagon-like peptide-1 (glp-1) derivatives
JP4949838B2 (en) * 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス New GLP-1 derivative
WO2005028516A2 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN101380476A (en) * 2003-09-19 2009-03-11 诺沃挪第克公司 Albumin-binding derivatives of therapeutic peptides
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
WO2005046716A1 (en) * 2003-11-13 2005-05-26 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
PL3300721T5 (en) 2003-11-20 2025-11-17 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
CA2550217A1 (en) * 2003-12-12 2005-07-07 Michael A. Brownlee Glp-1 (9-36) methods and compositions
WO2005058954A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
CN1318587C (en) * 2004-04-30 2007-05-30 成都芝田生物工程有限公司 Recombination preparation method of amidating Exendin-4 polypeptide
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
AU2012202855B2 (en) * 2004-09-03 2015-02-26 Philipps-Universitat Marburg GLP-1 and exendin related invention
DE102004043153B4 (en) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Invention relating to GLP-1 and exendin
JP5107713B2 (en) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス Delayed exendin-4 compound
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
EP1814581B1 (en) * 2004-11-12 2016-03-16 Novo Nordisk A/S Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
DE102004058306A1 (en) * 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Process for the preparation of carboxy-terminally amidated peptides
US8716221B2 (en) 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
EP1845105A4 (en) * 2005-01-14 2009-02-18 Wuxi Grandchamp Pharmaceutical Modified exendins and uses thereof
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8211430B2 (en) 2005-03-04 2012-07-03 Curedm Group Holdings, Llc Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
WO2006097535A2 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
AU2006224537A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CA2607150C (en) 2005-05-04 2014-08-05 Bjarne Due Larsen Glucagon-like-peptide-2 (glp-2) analogues
EA013821B1 (en) 2005-05-25 2010-08-30 Кьюрдм, Инк. Human proislet peptide, derivatives and analogs thereof, and methods of using same
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8466104B2 (en) 2005-08-26 2013-06-18 Abbvie Inc. Therapeutically active alpha MSH analogues
DE102006031962A1 (en) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidated insulin glargine
DE102006031955A1 (en) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Process for the preparation of dibasic B chain end insulin analogs
ATE524493T1 (en) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp EXENDIN FUSION PROTEINS
BRPI0715160A2 (en) 2006-08-08 2013-06-11 Sanofi Aventis arylamimoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, drugs comprising these compounds, and their use
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
KR101527233B1 (en) 2006-11-08 2015-06-08 질랜드 파마 에이/에스 The selective glucagon-like peptide-2 (GLP-2) analog
JP2010043001A (en) * 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Glp-1 derivative and use thereof
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
WO2008098693A2 (en) * 2007-02-16 2008-08-21 Bayer Healthcare Ag Convergent synthesis of glp-1
WO2008149346A2 (en) 2007-06-04 2008-12-11 Ben Gurion University Of The Negev Research And Development Authority Enhanced sensitivity polymerase chain reactions
ATE520714T1 (en) 2007-06-15 2011-09-15 Zealand Pharma As GLUCAGON ANALOGUE
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
HRP20150330T1 (en) 2007-08-30 2015-06-19 Curedm Group Holdings, Llc Compositions and methods of using proislet peptides and analogs thereof
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
JP5476304B2 (en) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス Glucagon-like peptide-1 derivatives and their pharmaceutical use
DK2205624T3 (en) * 2007-10-27 2017-01-02 Corden Pharma Colorado Inc Insulinotropic peptide synthesis using solid state and solution phase combination techniques
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Novel crystalline diphenylazetidinone hydrates and process for their preparation
DK2597103T3 (en) 2007-11-16 2017-02-13 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
DE102008003568A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
NZ586590A (en) 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
AU2009203810B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008025007A1 (en) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes and for cartilage regeneration
DE102008025008A1 (en) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes
DE102008003566A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
BRPI0915282A2 (en) * 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp gip-based mixed agonists for the treatment of metabolic disorders and obesity
CA2726894A1 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CN102112157B (en) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 Conjugated proteins with prolonged in vivo efficacy
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
LT2349324T (en) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SI2373681T1 (en) * 2008-12-10 2017-05-31 Glaxosmithkline Llc Corporation Service Company Pharmaceutical compositions of albiglutide
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
MX2011006313A (en) 2008-12-15 2011-09-27 Zealand Pharma As Glucagon analogues.
PL2370462T3 (en) 2008-12-15 2015-01-30 Zealand Pharma As Glucagon analogues
PL2370461T3 (en) 2008-12-15 2014-03-31 Zealand Pharma As Glucagon analogues
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
EP2451471A1 (en) * 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Slow-acting insulin preparations
KR101853606B1 (en) * 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 Aqueous insulin preparations containing methionine
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
CN101987868B (en) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Derivative or pharmaceutically acceptable salt of GLP-1 analogue and application of derivative or pharmaceutically-acceptable salt of a GLP-1 analogue
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
ES2443016T3 (en) 2009-08-26 2014-02-17 Sanofi New crystalline hydrates of heteroaromatic fluoroglycosides, pharmaceutical products comprising these compounds, and their use
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
PT2329848E (en) 2009-11-13 2013-01-23 Sanofi Aventis Deutschland Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes
JP5832439B2 (en) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Pharmaceutical composition comprising a GLP-1 agonist, insulin and methionine
EP2324853B1 (en) 2009-11-13 2015-08-26 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on to metformin in the treatment of diabetes type 2
CN102711804B (en) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 Pharmaceutical composition comprising a GLP-1 agonist and methionine
DE102010011919A1 (en) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Liquid composition, useful for treating e.g. type II diabetes mellitus, and/or obesity, comprises a glucagon-like peptide-1 agonist and/or its salt e.g. exendin-4, optionally an adjuvant and methionine
JP2011105609A (en) * 2009-11-13 2011-06-02 Sanofi-Aventis Deutschland Gmbh Method for treating type-2 diabetes including add-on therapy to metformin
AU2009238272B2 (en) * 2009-11-13 2014-05-08 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
NZ601167A (en) 2010-01-20 2014-12-24 Zealand Pharma As Treatment of cardiac conditions
JP5980689B2 (en) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
SI2525834T1 (en) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
JP5992836B2 (en) 2010-03-01 2016-09-14 ノヴォ ノルディスク アー／エス Preparative RP-HPLC method for purifying peptides
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
WO2011134471A1 (en) 2010-04-27 2011-11-03 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
JP2013525491A (en) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
CN101891823B (en) * 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 Exendin-4 and analog fusion protein thereof
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
UY33462A (en) 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN103179978A (en) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
HRP20180425T1 (en) 2010-12-16 2018-04-20 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING AGONIST GLP-1 AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRILIC ACIDS
CN107375909A (en) 2011-02-02 2017-11-24 赛诺菲-安万特德国有限公司 Prevent hypoglycemia in diabetes B patient
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683701B1 (en) 2011-03-08 2014-12-24 Sanofi Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US20120277147A1 (en) 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
BR112013026195A2 (en) 2011-04-12 2016-11-29 Novo Nordisk As double acylated glp-1 derivatives
ES2556466T3 (en) 2011-05-13 2016-01-18 Sanofi-Aventis Deutschland Gmbh Lixisenatide and metformin for the treatment of type 2 diabetes
US20130040878A1 (en) 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US8735349B2 (en) 2011-05-13 2014-05-27 Sanofi-Aventis Deutschland Gmbh Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HUE028568T2 (en) 2011-10-04 2016-12-28 Sanofi Aventis Deutschland Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
US20130096059A1 (en) 2011-10-04 2013-04-18 Jens Stechl Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
CA2851690C (en) 2011-10-28 2022-07-26 Sanofi-Aventis Deutschland Gmbh Treatment protocol of diabetes type 2
CN104144704B (en) 2011-11-03 2018-03-23 西兰制药公司 The receptor agonist peptides gastrin conjugates of GLP 1
CN103087174B (en) * 2011-11-03 2015-11-18 华东师范大学 A kind of GLP-1 derivative DLG3312 and solid-state chemical reaction method method thereof
JP2015500823A (en) 2011-12-09 2015-01-08 ノヴォ ノルディスク アー／エス GLP-1 agonist
EA201490982A1 (en) 2011-12-23 2015-01-30 Зилэнд Фарма А/С ANALOGUE GLUACAGONA
PT2827845T (en) 2012-03-22 2019-03-29 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
SMT201800491T1 (en) 2012-03-22 2018-11-09 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
IN2014MN02304A (en) 2012-05-03 2015-08-07 Zealand Pharma As
JP6517690B2 (en) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス Tablet formulation containing peptide and delivery agent
CN109456400A (en) 2012-07-23 2019-03-12 西兰制药公司 Glucagon analogue
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analog
CN105142621A (en) 2012-10-24 2015-12-09 国家健康科学研究所 Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting Beta-cell survival
WO2014077575A1 (en) * 2012-11-13 2014-05-22 다인바이오 주식회사 Agar-derived neoagarooligosaccharide composite composition prepared by daga enzyme reaction and having anti-obesity and anti-diabetes effects
KR20140088837A (en) * 2013-01-03 2014-07-11 한미약품 주식회사 Insulinotropic peptide derivative wherein its N-terminal charge is modified
TWI641381B (en) 2013-02-04 2018-11-21 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogs and/or insulin derivatives
SG11201506888VA (en) 2013-04-03 2015-09-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
ES2688462T3 (en) 2013-05-02 2018-11-02 Novo Nordisk A/S Oral dosage of GLP-1 compounds
AR096789A1 (en) * 2013-07-04 2016-02-03 Novo Nordisk As DERIVATIVES OF GLP-1 SIMILAR PEPTIDES AND USES OF THE SAME
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
RS57632B1 (en) 2013-10-17 2018-11-30 Zealand Pharma As Acylated glucagon analogues
JP6657101B2 (en) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ Compounds for the treatment of diabetes and disease complications resulting therefrom
JP2017503474A (en) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ Glucagon-GLP-1-GIP triple agonist compound
CN105849122B (en) 2013-11-06 2021-04-30 西兰制药公司 GIP-GLP-1 dual agonist compounds and methods
CN103613657B (en) * 2013-11-28 2016-01-13 孙玉琨 Shorten Exendin4 and the genetically engineered application thereof of peptide chain
JP6735674B2 (en) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ Stabilized pharmaceutical formulation of insulin aspart
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR101768446B1 (en) * 2014-03-21 2017-08-17 애니젠 주식회사 Novel Exenatide Analogs and Uses thereof
TWI705973B (en) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Gip agonist compounds and methods
MA41138B1 (en) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
AR103415A1 (en) 2015-01-16 2017-05-10 Sanofi Aventis Deutschland TREATMENT OF PEDIATRIC PATIENTS WITH MELLITUS DIABETES OF TYPE 2
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
PL3283507T3 (en) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylated glucagon analogue
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
ES2894629T3 (en) 2017-06-16 2022-02-15 Zealand Pharma As Dosage Guidelines for Administration of Glucagon-Like Peptide-2 (GLP-2) Analogues
FR3082426A1 (en) 2018-06-14 2019-12-20 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR
EP3658115B1 (en) 2017-07-27 2022-02-23 Adocia Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
HRP20240485T1 (en) 2017-08-24 2024-07-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
EP3774837A1 (en) * 2018-04-10 2021-02-17 Sanofi-Aventis Deutschland GmbH Method for cleavage of solid phase-bound peptides from the solid phase
ES2928207T3 (en) 2018-04-10 2022-11-16 Sanofi Aventis Deutschland Synthesis of lixisenatide with hooding
FR3083700B1 (en) 2018-07-13 2021-03-12 Adocia THERMOSTABLE FORMULATION OF HUMAN INSULIN A21G
EP3628683A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
TWI799680B (en) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 Process for preparing a gip/glp1 dual agonist
CN109721653B (en) * 2019-03-05 2023-02-03 嘉兴学院 A kind of glucagon-like peptide-1 fragment analogue and its application
US20210093698A1 (en) 2019-09-13 2021-04-01 Sanofi Treatment of type 2 diabetes mellitus
EP3858373A1 (en) 2020-01-31 2021-08-04 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
MX2022009844A (en) 2020-02-18 2022-09-05 Novo Nordisk As Glp-1 compositions and uses thereof.
EP3915571A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP3915572A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP4259646A1 (en) * 2020-12-11 2023-10-18 IP2IPO Innovations Limited Novel compounds
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
TW202327643A (en) 2021-09-10 2023-07-16 丹麥商西蘭製藥公司 Process for formulating compositions comprising glucagon-like-peptide-2(glp-2) analogues
CA3241692A1 (en) 2021-12-23 2023-06-29 Claes MELANDER Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
GB202308304D0 (en) 2023-06-02 2023-07-19 Univ Ulster A fusion peptide for activation of the apj and/or glp-1 receptors
WO2024256632A1 (en) 2023-06-15 2024-12-19 Novo Nordisk A/S Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin
TW202535919A (en) 2023-12-28 2025-09-16 丹麥商西蘭製藥公司 Formulations of glucagon-like-peptide-2 (glp-2) analogues and their uses

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288627A (en) 1980-02-12 1981-09-08 Phillips Petroleum Company Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK0531372T4 (en) 1990-05-09 2004-08-09 Novozymes As Cellulase preparation comprising an endoglucanase enzyme
DK36392D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1998005351A1 (en) * 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
ES2283025T3 (en) 1996-08-30 2007-10-16 Novo Nordisk A/S DERIVATIVES OF GLP-1.1.
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
AU724326B2 (en) * 1996-09-09 2000-09-14 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
AU5065198A (en) * 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
DE69831673C5 (en) * 1997-01-07 2015-01-22 Amylin Pharmaceuticals, Llc USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD CONSUMPTION
JP2001512307A (en) 1997-02-05 2001-08-21 １１４９３３６ オンタリオ インコーポレーテッド Polynucleotides encoding proexendin and methods for making and using the same
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
CA2299425A1 (en) * 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
EP1066314B1 (en) * 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
CA2309356C (en) * 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
CA2320371C (en) 1998-02-13 2012-01-17 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
WO1999043708A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
CA2321026A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6451974B1 (en) * 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
CN1372570A (en) * 1999-04-30 2002-10-02 安米林药品公司 Modified exendin and exendin agonists
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
MXPA04012497A (en) * 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 and methods for treating diabetes.
WO2004035623A2 (en) * 2002-10-02 2004-04-29 Zealand Pharma A/S Stabilized exendin-4 compounds

Also Published As

Publication number Publication date
DK1329458T3 (en) 2012-07-16
EP1196444B8 (en) 2003-08-06
CA2680437A1 (en) 2001-01-18
AU781338B2 (en) 2005-05-19
CN1376166A (en) 2002-10-23
EP1196444B1 (en) 2003-06-04
IL147293A (en) 2007-12-03
AU2005203735B2 (en) 2009-03-19
US20070111940A1 (en) 2007-05-17
JP2014169296A (en) 2014-09-18
DE60003182T2 (en) 2004-05-06
EP1329458B1 (en) 2012-03-28
EP1196444A1 (en) 2002-04-17
ES2384963T3 (en) 2012-07-16
ES2529578T3 (en) 2015-02-23
ES2384963T9 (en) 2012-10-16
CY2013032I2 (en) 2015-11-04
SI2112161T1 (en) 2015-02-27
ATE242267T1 (en) 2003-06-15
FR13C0021I1 (en) 2013-05-03
EP1329458A2 (en) 2003-07-23
ATE551362T1 (en) 2012-04-15
AU2005203735A1 (en) 2005-09-29
DE60003182D1 (en) 2003-07-10
IL206445A0 (en) 2011-07-31
EP1329458A3 (en) 2003-12-17
JP2011102305A (en) 2011-05-26
WO2001004156A1 (en) 2001-01-18
SI1329458T1 (en) 2012-07-31
CN1229390C (en) 2005-11-30
ES2200892T3 (en) 2004-03-16
EP1329458B9 (en) 2012-09-12
IL185763A0 (en) 2008-01-06
PT1196444E (en) 2003-10-31
CY1113347T1 (en) 2016-06-22
EP1076066A1 (en) 2001-02-14
JP2003505347A (en) 2003-02-12
NZ517012A (en) 2003-02-28
EP2112161A2 (en) 2009-10-28
JP4332314B2 (en) 2009-09-16
PT1329458E (en) 2012-07-03
DK1196444T3 (en) 2003-09-29
JP5414144B2 (en) 2014-02-12
BE2013C033I2 (en) 2019-10-16
HK1135119A1 (en) 2010-05-28
DK1329458T5 (en) 2013-02-11
IL147293A0 (en) 2002-08-14
JP5553742B2 (en) 2014-07-16
EP2112161A3 (en) 2010-04-28
CA2378431A1 (en) 2001-01-18
DK2112161T3 (en) 2015-01-19
LU92175I2 (en) 2013-05-27
IL206445A (en) 2011-09-27
IL185763A (en) 2012-04-30
AU5966000A (en) 2001-01-30
HK1058046A1 (en) 2004-04-30
EP2112161B1 (en) 2014-11-05
JP2007001987A (en) 2007-01-11
CA2378431C (en) 2010-02-09
CY2013032I1 (en) 2015-11-04
PT2112161E (en) 2015-02-10

Similar Documents

Publication Publication Date Title
FR13C0021I2 (en) EXENDIN-4 CONJUGATES AND THEIR MEDICAL USE
TR200103469T2 (en) Prevention and treatment of amyloidogenic disease
DK0749317T3 (en) Therapeutic applications of dimeric products of bactericidal / permeability enhancing protein
NO20015584L (en) Long-lasting insulin-tropic peptides and conjugates and use in the manufacture of medicaments for treatment
DK1137762T3 (en) Treatment of Pompe disease
DE69838986D1 (en) POLYPEPTIDES, THEIR PREPARATION AND USE
DE69814394D1 (en) USE OF LEVOBUPIVACAIN
ATE232396T1 (en) OXIDATED THYMOSINE BETA 4
EA200300852A1 (en) CONJUGATES NEIBLAST WITH POLYMERS AND METHODS OF THEIR APPLICATION
BR9007115A (en) NEW TROMBOLITICO
TR200000455T2 (en) The use of fanquinone in the treatment of Alzheimer's disease.
TR199901385T2 (en) Piperidin t�revleri.
ATE428438T1 (en) MEDICAL COMPOSITION CONTAINING TCF-II
NO20034453D0 (en) Use of CD25-binding molecules in steroid-resistant patients
SE8802323D0 (en) 8ALFA-ACYLAMINOERGOLINE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
DE69929124D1 (en) Application-specific coding of medical instruments for introduction into a patient's body